Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.4.1 (
myosin ATPase
)
1,140
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The p21-activated kinase (PAK) family includes several enzyme isoforms regulated by the GTPases Rac1 and Cdc42. PAK1, found in brain, muscle and spleen, has been implicated in triggering cytoskeletal rearrangements such as the dissolution of stress fibers and reorganization of focal complexes. The role of the more widely distributed
PAK2
in controlling the cytoskeleton has been less well studied. Previous work has demonstrated that
PAK2
can monophosphorylate the myosin II regulatory light chain and induce retraction of permeabilized endothelial cells. In this report we characterize
PAK2
's morphological and biochemical effect on intact endothelial cells utilizing microinjection of constitutively active
PAK2
. Under these conditions we observed a modification of the actin cytoskeleton with retraction of endothelial cell margins accompanied by an increase in monophosphorylation of myosin II. Selective inhibitors were used to analyze the mechanism of action of
PAK2
. Staurosporine, a direct inhibitor of
PAK2
, largely prevented the action of microinjected
PAK2
in endothelial cells. Butanedione monoxime, a non-specific
myosin ATPase
inhibitor, also inhibited the effects of
PAK2
implicating myosin in the changes in cytoskeletal reorganization. In contrast, KT5926, a specific inhibitor of myosin light chain kinase was ineffective in preventing the changes in morphology and the actin cytoskeleton. The additional finding that endogenous
PAK2
associates with myosin II is consistent with the proposal that cell retraction and cytoskeletal rearrangements induced by microinjected
PAK2
depend on the direct activation of myosin II by
PAK2
monophosphorylation of the regulatory light chain.
...
PMID:Endothelial cell retraction is induced by PAK2 monophosphorylation of myosin II. 1063 34